These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652 [TBL] [Abstract][Full Text] [Related]
6. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597 [TBL] [Abstract][Full Text] [Related]
7. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Corso A; Barbarano L; Mangiacavalli S; Spriano M; Alessandrino EP; Cafro AM; Pascutto C; Varettoni M; Bernasconi P; Grillo G; Carella AM; Montalbetti L; Lazzarino M; Morra E Leuk Lymphoma; 2010 Feb; 51(2):236-42. PubMed ID: 20001242 [TBL] [Abstract][Full Text] [Related]
9. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714 [TBL] [Abstract][Full Text] [Related]
10. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970 [TBL] [Abstract][Full Text] [Related]
11. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337 [TBL] [Abstract][Full Text] [Related]
13. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
14. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
15. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma. Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960 [TBL] [Abstract][Full Text] [Related]
16. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715 [TBL] [Abstract][Full Text] [Related]
17. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914 [TBL] [Abstract][Full Text] [Related]
18. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830 [TBL] [Abstract][Full Text] [Related]
19. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Dimopoulos MA; Beksac M; Benboubker L; Roddie H; Allietta N; Broer E; Couturier C; Mazier MA; Angermund R; Facon T Haematologica; 2013 Aug; 98(8):1264-72. PubMed ID: 23716559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]